A simplified regimen of targeted antifungal prophylaxis in liver transplant recipients: A single‐center experience. Issue 2 (6th March 2018)

• Record Type: Journal Article
• Authors: Lavezzo, B.; Patrono, D.; Tandoi, F.; Martini, S.; Fop, F.; Ballerini, V.; Stratta, C.; Skurzak, S.; Lupo, F.; Strignano, P.; Donadio, P.P.; Salizzoni, M.; Romagnoli, R.; De Rosa, F.G.
• Is Part Of: Transplant infectious disease. Volume 20:Issue 2(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-03-06
• Subjects: amphotericin B -- invasive fungal infection -- liver transplant -- targeted prophylaxis; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12859
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: Background: Invasive fungal infection (IFI) is a severe complication of liver transplantation burdened by high mortality. Guidelines recommend targeted rather than universal antifungal prophylaxis based on tiers of risk. Methods: We aimed to evaluate IFI incidence, risk factors, and outcome after implementation of a simplified two‐tiered targeted prophylaxis regimen based on a single broad‐spectrum antifungal drug (amphotericin B). Patients presenting 1 or more risk factors according to literature were administered prophylaxis. Prospectively collected data on all adult patients transplanted in Turin from January 2011 to December 2015 were reviewed. Results: Patients re‐transplanted before postoperative day 7 were considered once, yielding a study cohort of 581 cases. Prophylaxis was administered to 299 (51.4%) patients; adherence to protocol was 94.1%. Sixteen patients developed 18 IFIs for an overall rate of 2.8%. All IFI cases were in targeted prophylaxis group; none of the non‐prophylaxis group developed IFI. Most cases (81.3%) presented within 30 days after transplantation during prophylaxis; predominant pathogens were molds (94.4%). Only 1 case of candidemia was observed. One‐year mortality in IFI patients was 33.3% vs 6.4% in patients without IFI ( P = .001); IFI attributable mortality was 6.3%. At multivariate analysis, significant risk factors for IFI were renal replacement therapy (OR = 8.1) and re‐operation (OR = 5.2). Conclusions: The implementation of a simplified targeted prophylaxis regimen appeared to be safe and applicable and was associated with low IFI incidence and mortality. Association of IFI with re‐operation and renal replacement therapy calls for further studies to identify optimal prophylaxis in this subset of patients.